MAP Pharmaceuticals

MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. The company's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Mountain View, California.